Martin van den Bent

Martin van den Bent

UNVERIFIED PROFILE

Are you Martin van den Bent?   Register this Author

Register author
Martin van den Bent

Martin van den Bent

Publications by authors named "Martin van den Bent"

Are you Martin van den Bent?   Register this Author

100Publications

2873Reads

48Profile Views

Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.

Neurology 2019 Jun 10;92(24):e2754-e2763. Epub 2019 May 10.

From the University Medical Center & German Cancer Research Center (M.N., F.S., I.H., P.K., M.P., M.B., W.W.), Heidelberg, Germany; EORTC Headquarters (T.G., V.G.), Brussels, Belgium; Brain Tumor Center at Erasmus MC Cancer Institute (J.E.C.B., W.T., M.J.v.d.B.), Rotterdam, the Netherlands; Medical Oncology Department (A.A.B.), AUSL-Bologna-IRCCS Scienze Neurologiche, Bologna, Italy; Haaglanden Medical Center (M.J.B.T.), the Hague; Leiden University Medical Center (M.J.B.T.), the Netherlands; Institut Gustave Roussy (J.D.), Villejuif; Sorbonne Université (A.I.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris; Institut de Cancerologie de l'Ouest (ICO)-Centre Rene Gauducheau (M.C.), Saint-Herblain, France; Leuven Cancer Institute-KU Leuven (P.M.C.), Belgium; Department of Neurology and Brain Tumor Center (M.W.), University Hospital and University of Zurich, Switzerland; Institut Régional du Cancer Montpellier (M.F.); University of Lille (E.L.R.), U-1192, Inserm; CHU Lille (E.L.R.), General and Stereotaxic Neurosurgery Service; Oscar Lambret Center (E.L.R.), Neurology, Lille, France; Department of Neurology (M.P.), Medical Faculty Mannheim, Heidelberg University, Germany; and Department of Neurology (M.N.), Medical University Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007643DOI Listing
June 2019

How we treat patients with leptomeningeal metastases.

ESMO Open 2019 21;4(Suppl 2):e000507. Epub 2019 May 21.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555600PMC
May 2019

Association Between Supratotal Glioblastoma Resection and Patient Survival: A Systematic Review and Meta-Analysis.

World Neurosurg 2019 Apr 17. Epub 2019 Apr 17.

Department of Radiology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.04.092DOI Listing
April 2019

Novel methods to diagnose leptomeningeal metastases in breast cancer.

Neuro Oncol 2019 Mar;21(4):428-439

Erasmus MC Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422430PMC
March 2019

On high-risk, low-grade glioma: What distinguishes high from low?

Cancer 2019 Jan 4;125(2):174-176. Epub 2018 Dec 4.

The Brain Tumor Center at Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31834DOI Listing
January 2019

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies.

Cytometry B Clin Cytom 2018 11 3;94(6):928-934. Epub 2018 Sep 3.

Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21641DOI Listing
November 2018

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.

Acta Neuropathol Commun 2018 11 23;6(1):126. Epub 2018 Nov 23.

Department of Pathology, Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-018-0633-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251173PMC
November 2018

Preface.

Handb Clin Neurol 2018 ;149:ix

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-811161-1.09988-6DOI Listing
September 2018

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

Lancet Oncol 2018 09 13;19(9):1170-1179. Epub 2018 Aug 13.

The Brain and Spine Institute (ICM), Sorbonne Université, The National Institute of Health and Medical Research (INSERM), National Centre for Scientific Research (CNRS), Public Assistance-Paris Hospitals (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183036
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30362-0DOI Listing
September 2018

First results on the DCVax phase III trial: raising more questions than providing answers.

Neuro Oncol 2018 Sep;20(10):1283-1284

Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120355PMC
September 2018

Grade II and III Oligodendroglioma and Astrocytoma.

Neurol Clin 2018 08 15;36(3):467-484. Epub 2018 Jun 15.

Department of Neurosurgery, University of California, San Francisco, Box 0112, 505 Parnassus Avenue M779, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ncl.2018.04.005DOI Listing
August 2018

Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.

Lancet Oncol 2018 08;19(8):e407-e418

Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center Rotterdam, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183035
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30356-5DOI Listing
August 2018

Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?

Neuro Oncol 2018 Jun;20(7):868-869

The Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007572PMC
June 2018

Pseudoprogression of brain tumors.

J Magn Reson Imaging 2018 May 7. Epub 2018 May 7.

Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175399PMC
May 2018

Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?

Am Soc Clin Oncol Educ Book 2018 May;38:158-167

From the Massachusetts General Hospital, Harvard Medical School, Boston, MA; Departments of Neurosurgery, Neurology, and Internal Medicine (Oncology), Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Department of Neurology, The Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, Netherlands; Division of Neuro-Oncology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_199247DOI Listing
May 2018

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC).

Acta Neuropathol 2018 03 25;135(3):481-484. Epub 2018 Jan 25.

The Brain Tumor Center at Erasmus MC Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-018-1808-0DOI Listing
March 2018

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Nat Rev Clin Oncol 2017 Nov 4;14(11):695-707. Epub 2017 Jul 4.

Austin Health and Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.95DOI Listing
November 2017

Lomustine and Bevacizumab in Progressive Glioblastoma.

N Engl J Med 2017 11;377(20):1954-1963

From the University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B., M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the Netherlands; the Medical Oncology Department, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.); Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 7225, Sorbonne Universités, University Pierre and Marie Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Épinière, Paris (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain (M.C.), Institut Régional du Cancer Montpellier, Montpellier (M.F.), and Centre Hospitalier Régional Universitaire de Lille, Lille (E.L.R., F.D.) - all in France; and the Departments of Oncology and Neurology, University Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707358DOI Listing
November 2017

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Neuro Oncol 2017 Aug;19(8):1119-1126

Tel-Aviv Sourasky Medical Center, Tel-Aviv University; European Organization for Research and Treatment of Cancer, Brussels (EORTC); National Institutes of Health (M.R.M.); University of Alabama at Birmingham; Princess Margaret Cancer Centre, University of Toronto; Lausanne University Hospital; NRG Oncology Statistics and Data Management Center; Odette Cancer Centre and Sunnybrook Health Sciences Centre, University of Toronto; Samsung Medical Center, Sungkyunkwan University School of Medicine; Edinburgh Cancer Centre; Mayo Clinic; Robert-Janker Clinic at the University of Bonn Medical Centre, and MAASTRO clinic, GROW School for Oncology, Maastricht University Medical Centre; Miami Cancer Institute; Erasmus University Hospital; Dana-Farber Cancer Institute and Harvard Medical School; University of Zurich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570239PMC
August 2017

Imaging Correlates of Adult Glioma Genotypes.

Radiology 2017 08;284(2):316-331

From the Department of Radiology, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands (M.S.); and Brain Tumor Center, Erasmus MC Cancer Center, Rotterdam, the Netherlands (M.J.v.d.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2017151930DOI Listing
August 2017

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Lancet Oncol 2017 08 26;18(8):e430-e431. Epub 2017 Jul 26.

Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany; German Consortium of Translational Cancer Research, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30515-6DOI Listing
August 2017

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Neuro Oncol 2017 Jul;19(7):965-975

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of Neurology, Northwestern University, Chicago, Illinois; Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois; Department of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas; Department of Radiation Oncology, The University of Texas M.D.Anderson Cancer Center, Houston, Texas; AbbVie Inc., North Chicago, Illinois; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570193PMC
July 2017

Diffuse Infiltrating Oligodendroglioma and Astrocytoma.

J Clin Oncol 2017 Jul 22;35(21):2394-2401. Epub 2017 Jun 22.

Martin J. van den Bent and Johan M. Kros, Erasmus Medical Center (MC) Cancer Institute; Marion Smits, Erasmus MC, Rotterdam, the Netherlands; and Susan M. Chang, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6737DOI Listing
July 2017

Response Assessment in Neuro-Oncology Clinical Trials.

J Clin Oncol 2017 Jul 22;35(21):2439-2449. Epub 2017 Jun 22.

Patrick Y. Wen and Eudocia Q. Lee, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Susan M. Chang, University of California, San Francisco, San Francisco, CA; Michael A. Vogelbaum, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Martin J. Van den Bent, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; and David R. Macdonald, London Regional Cancer Program, Western University, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516482PMC
July 2017

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Lancet Oncol 2017 06 5;18(6):e315-e329. Epub 2017 May 5.

Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany; German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30194-8DOI Listing
June 2017

Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence.

J Neurooncol 2017 Jun 24;133(2):237-246. Epub 2017 May 24.

Department of Neurology/Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2454-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529493PMC
June 2017

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Neuro Oncol 2017 05;19(5):614-624

Division of Neuro-Oncology, Department of Neurological Surgery, University of California San Francisco,San Francisco, California

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464438PMC
May 2017

Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.

Neuro Oncol 2017 05;19(5):719-725

Department of Neuro-oncology/Neurology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464441PMC
May 2017

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Neuro Oncol 2017 01 20;19(1):12-21. Epub 2016 Sep 20.

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (E.K.A., L.M.D.); Department of Neurology, University of Washington, Seattle, Washington (M.C.); Department of Neurology, University of Virginia, Charlottesville, Virginia (D.S.); Department of Neurology, VUmc Cancer Center, Amsterdam, Netherlands (J.C.R.); Department of Family Health, University of Texas Health Science Center, Houston, Texas (T.S.A.); Department of Neuro-Oncology, City of Health and Science Hospital, Torino, Italy (R.R.); Center for Neuro-Oncology, Dana-Farber Cancer Institute/ Brigham and Women's Center, Boston, Massachusetts (P.W.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Leiden University Medical Center, The Hague, Netherlands (J.A.F.K.); Department of Neurosurgery, Wayne State University, Detroit, Michigan (S.M.); Department of Neurosurgery, Kyoto University School of Graduate Medicine, Kyoto, Japan (Y.A.); Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois (A.C.); Department of Epilepsy and Surgery Center, Cleveland Clinic, Cleveland, Ohio (J.G.-M.); Department of Neurology, London Health Sciences Center, London, Ontario, Canada (D.R.M.); Department of Neurosurgery, Saitama Medical University, Saitama, Japan (R.N.); Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan (A.S.); Service Neurologie Mazarin, CHU Pitie-Salpetriere, Paris, France (C.J.V.); Department of Neurology, University of Alabama, Birmingham, Alabama (P.W.); Department of Neuro-Oncology, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands (M.J.v.d.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193028PMC
January 2017

Low-grade and anaplastic oligodendroglioma.

Handb Clin Neurol 2016 ;134:361-80

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-802997-8.00022-0DOI Listing
December 2016

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.

Mol Oncol 2016 10 1;10(8):1296-304. Epub 2016 Jul 1.

Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds LS9 7TF, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2016.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423205PMC
October 2016

Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.

J Mol Diagn 2016 09 25;18(5):775-786. Epub 2016 Jul 25.

Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2016.06.002DOI Listing
September 2016

Oligodendrogliomas: a short history of clinical developments.

CNS Oncol 2015 ;4(5):281-5

Brain Tumor Center at Erasmus MC Cancer Center, Erasmus MC, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns.15.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082331PMC
August 2016

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Neuro Oncol 2016 Mar 9;18(3):388-400. Epub 2015 Sep 9.

Department of Pathology, Rotterdam, the Netherlands (H.J.D., P.N.A., J.M.K., W.N.M.D.); Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands (P.J.F.); Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, Paris, France (M.S., A.I.); Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (P.W.); Department of Pathology, Free University Medical Center, Amsterdam, the Netherlands (P.W.); Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands (R.E.); Department of Pathology, UMCU, Utrecht, the Netherlands (W.S.); Department of Neurology, St. Elisabeth Hospital, Tilburg, the Netherlands (C.T.); European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium (T.G.); Department of Neurology/Neuro-oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands (M.J.v.d.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767239PMC
March 2016

Chemotherapy in glioma.

CNS Oncol 2015 23;4(3):179-92. Epub 2015 Apr 23.

Department of Neurology/Neuro-Oncology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns.15.2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088309PMC
February 2016

Chemotherapy for low-grade glioma: when, for whom, which regimen?

Curr Opin Neurol 2015 Dec;28(6):633-938

Erasmus MC Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000257DOI Listing
December 2015

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.

Acta Neuropathol Commun 2015 Dec 23;3:88. Epub 2015 Dec 23.

Department of Neurology, Erasmus MC, Room Be 430A, POBox 2040, 3000 CA, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-015-0265-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690424PMC
December 2015

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Neuro Oncol 2015 Sep 5;17(9):1188-98. Epub 2015 Aug 5.

UCLA Neuro-Oncology Program and UCLA Brain Tumor Imaging Laboratory (BTIL), David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California (B.M.E., T.F.C.); Department of Radiological Sciences, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California (B.M.E., W.B.P.); Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany (M.B.); Department of Diagnostic Imaging, Warrne Alpert Medical School, Brown University, Providence, Rhode Island (J.B.); Department of Neuroradiology, Duke University School of Medicine, Durham, North Carolina (D.B.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (B.J.E.); Department of Radiology, Erasmus MC University, Rotterdam, Netherlands (M.S.); Department of Radiology and Biomedical Imaging, University of California - San Francisco, San Francisco, California (S.J.N., S.C.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (B.A., P.Y.W.); Medical and Scientific Affairs, ICON Medical Imaging, Warrington, Pennsylvania (G.G., D.Y.); Department of Neurooncology, National Center of Tumor Disease, University Clinic Heidelberg, Heidelberg, Germany (W.W.); Department of Neurological Surgery, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio (M.V.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota (E.G.); Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (J.K.-C.); Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland (L.S., P.J.); Department of Radiation Oncology, University of Toronto and Princess Margaret

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588759PMC
September 2015

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

Neuro Oncol 2015 Jul 16;17(7):935-41. Epub 2015 Feb 16.

Department of Neurology, Erasmus MC, Rotterdam, Netherlands (M.J.v.d.B., Y.G., K.v.Z., J.P., P.A.S.S., P.J.F.); Department of Pathology, Erasmus MC, Rotterdam, Netherlands (J.M.K.); Department of Neurology, Haaglanden MC, The Hague, Netherlands (M.K., M.T.); EORTC Headquarters, Brussels, Belgium (T.G.); Pathology Department, Leiden University Medical Center, Leiden, Netherlands (S.v.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762005PMC
July 2015

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

Eur J Cancer 2015 Jul 17;51(10):1321-30. Epub 2015 Apr 17.

VU University Medical Center, Department of Neurology, PO Box 7057, 1007 MB Amsterdam, The Netherlands; Medical Center Haaglanden, Department of Neurology, PO Box 432, 2501 CK The Hague, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.03.025DOI Listing
July 2015

Neuro-oncology: The many challenges of treating elderly glioblastoma patients.

Nat Rev Neurol 2015 Jul 19;11(7):374-5. Epub 2015 May 19.

Department of Neuro-Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2015.82DOI Listing
July 2015

Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials.

J Clin Oncol 2015 Jun 27;33(17):1943-50. Epub 2015 Apr 27.

Johan M. Kros and Karin Huizer, Erasmus Medical Center; Pim French and Martin J. van den Bent, Dr Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Aurelio Hernández-Laín, Hospital Universitario 12 de Octubre Reseach Institute, Madrid; Teresa Ribalta, Hospital Clínic, University of Barcelona, Barcelona, Spain; Gianluca Marucci, Bellaria Hospital, University of Bologna, Bologna; Bianca Pollo, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico "C. Besta," Milano, Italy; Alex Michotte, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel; David Jaminé, Nawal Bekka, Denis Lacombe, and Thierry Gorlia, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Elisabeth J. Rushing, Institute for Neuropathology, University Hospital of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0166DOI Listing
June 2015

Oligodendroglioma: pathology, molecular mechanisms and markers.

Acta Neuropathol 2015 Jun 6;129(6):809-27. Epub 2015 May 6.

Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-015-1424-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436696PMC
June 2015

Assessment methods and prevalence of cognitive dysfunction in patients with low-grade glioma: A systematic review.

J Rehabil Med 2015 Jun;47(6):481-8

Rijndam Rehabilitation Center, Rotterdam Neurorehabilitation Research (RoNeRes), PO Box 23181, NL-3001 KD Rotterdam, The Netherlands .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/16501977-1975DOI Listing
June 2015

Joint modeling of longitudinal health-related quality of life data and survival.

Qual Life Res 2015 Apr 14;24(4):795-804. Epub 2014 Oct 14.

Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-014-0821-6DOI Listing
April 2015

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells.

Cancer Lett 2015 Jan 8;356(2 Pt B):525-35. Epub 2014 Oct 8.

Department of Neurosurgery, Brain Tumor Center, Erasmus MC, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands; Department of Neurosurgery, Elizabeth Medical Hospital, Tilburg, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2014.09.049DOI Listing
January 2015

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.

J Neurooncol 2015 Jan 26;121(2):365-72. Epub 2014 Oct 26.

Department of Neuro-Oncology/Neurology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1641-9DOI Listing
January 2015

Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.

Neuro Oncol 2014 Dec 29;16(12):1570-4. Epub 2014 Oct 29.

Department of Neuro-oncology/Neurology, Erasmus M.C. Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232091PMC
December 2014

Facing the future of brain tumor clinical research.

Clin Cancer Res 2014 Nov;20(22):5591-600

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0835DOI Listing
November 2014

Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authors' reply.

Lancet Oncol 2014 Oct;15(11):e473-4

Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70453-XDOI Listing
October 2014

Pros and cons of current brain tumor imaging.

Neuro Oncol 2014 Oct;16 Suppl 7:vii2-11

Department of Radiological Sciences (B.M.E.), Department of Biomedical Physics, David Geffen School of Medicine at UCLA (B.M.E.); Department of Bioengineering, Henry Samueli School of Engineering and Applied Science at UCLA (B.M.E.); Brain Research Institute, David Geffen School of Medicine at UCLA (B.M.E., T.F.C.); UCLA Neuro-Oncology Program, David Geffen School of Medicine at UCLA, Los Angeles, California (B.M.E., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.); Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands (M.J.v.d.B.); Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195528PMC
October 2014

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Neuro Oncol 2014 Oct;16 Suppl 7:vii36-47

Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (P.Y.W., D.A.R.); University of California, Los Angeles School of Medicine, Los Angeles, California (T.F.C., B.M.E., W.B.P.); New York University Langone Medical Center, New York, New York (H.A.F.); Hoffmann-La Roche, Basel, Switzerland (L.A.); Department of Biostatistics, Mayo Clinic Rochester, Rochester, Minnesota (K.B.); Department of Neuro-radiology, University of Heidelberg, Heidelberg, Germany (M.B.); Department of Medical Oncology, Mayo Clinic Rochester, Rochester, Minnesota (J.B.); Brain Tumor Center, University of California, San Francisco, California (S.M.C., M.D.P.); Siemens Healthcare North America, Malvern, Pennsylvania (A.G.S.); Department of Neuro-Oncology, Erasmus M.C.-Daniel den Hoed Cancer Center, Rotterdam, Netherlands (M.v.d.B.); Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, Texas (W-K.A.Y.).

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/nou226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195530PMC
October 2014

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Neuro Oncol 2014 Sep 27;16(9):1176-85. Epub 2014 May 27.

Department of Neurology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington (M.C.); Department of Neuroscience, Division of Neuro-Oncology, University Hospital, Torino, Italy (R.S., R.R.); Department of Neurology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois (J.R.); Department of Neuro-Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands (D.B., W.B.); Departments of Neuro-Oncology Mazarin and Radiation Oncology, Pitie-Salpetriere Hospital and University Pierre et Marie Curie, Paris VI, Paris, France (S.T.); Austin Brain Tumor Center, Texas Oncology/US Oncology Research, Austin, Texas (M.D.G.); Department of Neuro-Oncology, University Hospital, Lille, France (E.L.R.); Department of Neurology, Oscar Lambret Center, Lille, France (E.L.R.); Department of Neurology, University of Michigan, Ann Arbor, Michigan (L.J.); Department of Neuro-oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands (M.v.d.B.); Department of Neurology, Dana-Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts (P.Y.W.); Department of Neurology and Oncology, Mayo Clinic Florida, Jacksonville, Florida (K.A.J.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136900PMC
September 2014

Are we done with dose-intense temozolomide in recurrent glioblastoma?

Neuro Oncol 2014 Sep 25;16(9):1161-3. Epub 2014 Jul 25.

Dr Daniel den Hoed Cancer Center Rotterdam, The Netherlands (M.J.v.d.B.); Dept Neuro-Oncology/Neurology Erasmus MC Cancer Institute, Rotterdam, The Netherlands (M.J.v.d.B., W.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136902PMC
September 2014

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

Lancet Oncol 2014 Aug;15(9):e395-403

Department of Neurooncology, Neurology Clinic & National Center for Tumor Diseases, University Hospital Heidelberg, Germany; German Consortium of Translational Cancer Research, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045147001
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(14)70011-7DOI Listing
August 2014

MGMT testing--the challenges for biomarker-based glioma treatment.

Nat Rev Neurol 2014 Jul 10;10(7):372-85. Epub 2014 Jun 10.

Department of Neuropathology, Heinrich Heine University, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2014.100DOI Listing
July 2014

Reply to M.C. Chamberlain.

J Clin Oncol 2014 Jul 16;32(21):2273-4. Epub 2014 Jun 16.

Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2878DOI Listing
July 2014